Bpgbio, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 4 to 16, 2027 · next Jan 4
- 2 fees due Feb 13 to 22, 2027 · next Feb 13
- 1 fee due May 19, 2027The maintenance fee for Bayesian Causal Relationship Network Models for Healthcare Diagnosis and Treatment Based on Patient Data (US 10,482,385) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Methods for Treatment of Oncological Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecules, or Environmental Influencers (US 10,519,504) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Jul 9 to 21, 2027 · next Jul 9
- 1 fee due Sep 17, 2027The maintenance fee for Topical Formulations Having Enhanced Bioavailability (US 10,588,859) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,588,859 | Topical Formulations Having Enhanced Bioavailability In force · High confidence | In force | High confidence | |
| US 10,668,028 | Methods and Use of Inducing Apoptosis in Cancer Cells In force · Medium confidence | In force | Medium confidence | |
| US 9,896,731 | Methods for Treatment of Oncological Disorders Using an Epimetabolic Shifter (Coenzyme Q10) In force · Medium confidence | In force | Medium confidence | |
| US 10,351,915 | Methods for Treatment of Oncological Disorders Using an Epimetabolic Shifter (Coenzyme Q10) In force · Medium confidence | In force | Medium confidence | |
| US 10,519,504 | Methods for Treatment of Oncological Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecules, or Environmental Influencers In force · High confidence | In force | High confidence | |
| US 11,028,446 | Methods for Treatment of Oncological Disorders Using an Epimetabolic Shifter (Coenzyme Q10) In force · High confidence | In force | High confidence | |
| US 12,209,285 | Methods for Treatment of Oncological Disorders Using an Epimetabolic Shifter (Coenzyme Q10) In force · High confidence | In force | High confidence | |
| US 11,305,016 | Vitamin D3 and Analogs Thereof for Treating Alopecia In force · Medium confidence | In force | Medium confidence | |
| US 8,454,945 | Topical Formulations Having Enhanced Bioavailability In force · High confidence | In force | High confidence | |
| US 11,400,058 | Intravenous Formulations of Coenzyme Q10 (CoQ10) and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 45: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned